Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2019—Qiagen launched its QIAseq Expanded Carrier Screening Panel, which provides identification of targets, genes, and other regions of interest responsible for more than 200 disease indications. The QIAseq panel is integrated with the company’s CLC Genomics Workbench and Clinical Insight (QCI)-Interpret for QIAseq to provide evidence-based, actionable insights.
November 2019—The U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared involve a new testing paradigm in which two enzyme immunoassays are run concurrently or sequentially, rather than the current two-step process in which a Western blot must be run after the initial EIA test.
November 2019—Memorial Sloan Kettering Cancer Center announced that the New York State Department of Health has issued an approval for its Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS) molecular assay. MSK-ACCESS was developed in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and has been clinically validated and implemented by members of MSK’s molecular diagnostics service.
November 2019—Randox introduced a research use only sPLA2-IIA assay for use on a range of clinical chemistry analyzers. The latex-enhanced immunoturbidimetric assay measures sPLA2-IIA mass levels.
November 2019—ChromaCode announced publication of a study by the Medical College of Wisconsin, Milwaukee, and Gundersen Medical Foundation, La Crosse, Wis., highlighting the performance and utility of the High-Definition PCR Tick-Borne Pathogen Panel RUO.
November 2019—Alcor Scientific introduced the miniiSED, the newest addition to its iSED family of erythrocyte sedimentation rate analyzers.
Biocare Medical released a mouse monoclonal antibody, p16 INK4a, for in vitro diagnostic use in the qualitative identification of the p16 INK4a protein by immunohistochemistry in formalin-fixed, paraffin-embedded human tissues.
November 2019—Hamilton Company introduced its compact Microlab Prep automated liquid handler, designed to fit on a lab bench or in a biological safety cabinet. The system consists of two independent pipetting channels and a high-speed multiprobe head as well as a configuration containing both pipetting technology types.
November 2019—AutoGen has introduced its fully automated Xtract 16+, for nucleic acid purification from molecular diagnostic, biological, clinical, and forensic sample types. The Xtract 16+ offers nucleic acid isolation from liquid biopsies, plasma, serum, and other body fluids and can process up to 16 samples simultaneously.
November 2019—Binding Site’s Immunologicals Group has expanded its line of antibodies and antigens for human coagulation testing applications. Prothrombin and glycerol-free prothrombin proteins are available as antigens, and antibody products include anti-human factor H, factor I, fibrinogen, fibronectin, plasminogen, prothrombin, thrombin, and von Willebrand factor.
